Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Tomoharu Miyashita

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3771-0773; OpenAlex author ID A5075738891. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2013: 4 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 17

  1. Prognostic significance of fibroblast senescence and senescence-associated secretory phenotype factor expression in the tumor microenvironment of pancreatic du… First author DOI 10.3892/or.2025.9031↗
  2. Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer. Co-author DOI 10.20517/cdr.2023.84↗
  3. Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.jcyt.2020.08.001↗
  4. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer. Co-author DOI 10.3892/mco.2020.2188↗
  5. [Intestinal Care Using L‒Glutamine Supplement and Probiotics Can Induce a Strong Anti‒Tumor Immune Response through the Induction of Mature Tertiary Lymphoid S… Co-author PMID 33976027↗
  6. [Significance of Preoperative Chemoradiotherapy for Resectable Pancreatic Cancer]. Co-author PMID 35046306↗
  7. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer. Co-author DOI 10.1111/cas.14668↗
  8. Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma. Co-author DOI 10.21873/anticanres.13750↗
  9. Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. Co-author DOI 10.3892/mco.2018.1579↗
  10. [A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemo… Co-author PMID 30692318↗
  11. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreat… Co-author DOI 10.1007/s10238-015-0394-x↗
  12. Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives. Co-author DOI 10.3892/ol.2017.6008↗
  13. [A case report of hepatic arterial infusion chemotherapy and RFA for liver metastasis from pancreatic cancer]. Co-author PMID 25731471↗
  14. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Co-author DOI 10.3892/mco.2013.133↗
  15. Hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases f… Co-author DOI 10.3892/mco.2013.152↗
  16. [Gemcitabine augments major histocompatibility complex class I-related chain A expression in pancreatic cancer]. Co-author PMID 24393861↗
  17. [Hepatic arterial infusion chemotherapy with gemcitabine for patients with postoperative liver metastases from pancreatic cancer]. Co-author PMID 24393883↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Isamu Makino · 13 shared papers, 2013–2026 · strength 1.08
  2. Tetsuo Ohta · 12 shared papers, 2013–2021 · strength 0.76
  3. Hidehiro Tajima · 12 shared papers, 2013–2021 · strength 0.76
  4. Takeo Shimasaki · 2 shared papers, 2024–2026 · strength 0.56
  5. Mitsuyoshi Okazaki · 5 shared papers, 2018–2021 · strength 0.48
  6. Masahiro Uehara · 2 shared papers, 2020–2024 · strength 0.37
  7. Toshinari Minamoto · 2 shared papers, 2020–2024 · strength 0.37
  8. Itasu Ninomiya · 6 shared papers, 2013–2021 · strength 0.36
  9. Shintaro Yagi · 1 shared paper, 2026 · strength 0.32
  10. Yuto Kitano · 1 shared paper, 2026 · strength 0.32
  11. Nobuhiko Ueda · 1 shared paper, 2021 · strength 0.12
  12. Hiroyuki Takamura · 1 shared paper, 2021 · strength 0.12
  13. Tatsuo Kumai · 1 shared paper, 2021 · strength 0.11
  14. Shigenori Goto · 1 shared paper, 2021 · strength 0.11
  15. Shuichi Kaneko · 1 shared paper, 2021 · strength 0.11
  16. Taro Yamashita · 1 shared paper, 2021 · strength 0.11
  17. Yoshio Sakai · 1 shared paper, 2021 · strength 0.11
  18. Yoshimichi Sai · 2 shared papers, 2013 · strength 0.05
  19. Toshifumi Gabata · 2 shared papers, 2013 · strength 0.05
  20. Akira Nakayama · 1 shared paper, 2014 · strength 0.04
  21. Osamu Matsui · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.